Dmytro Kharkov

Syndax Pharmaceuticals expands orphan drug access via new alliance

Syndax Pharmaceuticals expands orphan drug access via new alliance
@Syndax: Syndax expands drug access

Syndax Pharmaceuticals has announced a strategic collaboration with the World Orphan Drug Alliance (WODA) to enhance the availability of Revuforj® (revumenib) through a Managed Access Program.

This partnership aims to provide a clear route for patients to access Revuforj in areas where the drug might not be obtainable otherwise. Such initiatives are vital as they address the challenges of accessibility for innovative treatments in underserved regions. Patients and healthcare providers are expected to benefit significantly from this collaboration, as it bridges gaps in healthcare distribution and offers a potential lifeline for those in need.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.